Compare
Theriva Biologics, Inc. vs Jaguar Health, Inc. vs China SXT Pharmaceuticals, Inc. vs Cue Biopharma, Inc.
| Latest fiscal year | Theriva Biologics, Inc. TOVX | Jaguar Health, Inc. JAGX | China SXT Pharmaceuticals, Inc. SXTC | Cue Biopharma, Inc. CUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | $11.51M | $1.14M | $27.47M |
| Revenue growth (YoY) | n/a | -1.5% | -34.6% | +195.7% |
| Gross margin | n/a | 67.2% (computed) | 21.9% | n/a |
| Operating margin | n/a | -398.8% | -625.9% | -96.7% |
| Net margin | n/a | -465.4% | -545.2% | -96.9% |
| Net income | -$23.74M | -$53.58M | -$6.21M | -$26.60M |
| EPS (Diluted) | -$2.08 | -$22.97 | -$9.13 | -$0.28 |
| Operating cash flow | -$16.67M | -$23.69M | -$4.02M | -$21.69M |
| Free cash flow | -$16.70M | n/a | n/a | -$21.86M |
| Cash & equivalents | $13.06M | $968.0K | $28.18M | $27.14M |
| Total assets | $38.24M | $38.32M | $34.75M | $42.21M |
| Total liabilities | $22.86M | $57.01M | $5.05M | $15.78M |
| Shareholders' equity | $15.38M | -$18.69M | $29.71M | $26.43M |
| Return on year-end equity | -154.3% | n/a | -20.9% | -100.6% |
| Shares outstanding | 35.69M | n/a | n/a | 96.62M |
Revenue, most recent five fiscal years
| Fiscal year | Theriva Biologics, Inc. | Jaguar Health, Inc. | China SXT Pharmaceuticals, Inc. | Cue Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2011-12-31 | $11.51M Ended 2025-12-31 | $1.14M Ended 2026-03-31 | $27.47M Ended 2025-12-31 |
| 1 year earlier | $2.61M Ended 2010-12-31 | $11.69M Ended 2024-12-31 | $1.74M Ended 2025-03-31 | $9.29M Ended 2024-12-31 |
| 2 years earlier | n/a | $9.76M Ended 2023-12-31 | $1.93M Ended 2024-03-31 | $5.49M Ended 2023-12-31 |
| 3 years earlier | n/a | $11.96M Ended 2022-12-31 | $1.97M Ended 2023-03-31 | $1.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $4.33M Ended 2021-12-31 | $2.60M Ended 2022-03-31 | $14.94M Ended 2021-12-31 |